<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Haematol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2141</journal-id><journal-id journal-id-type="publisher-id">BJH</journal-id><journal-title-group><journal-title>British Journal of Haematology</journal-title></journal-title-group><issn pub-type="ppub">0007-1048</issn><issn pub-type="epub">1365-2141</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26147087</article-id><article-id pub-id-type="pmc">4832298</article-id><article-id pub-id-type="doi">10.1111/bjh.13542</article-id><article-id pub-id-type="publisher-id">BJH13542</article-id><article-categories><subj-group subj-group-type="overline"><subject>Correspondence</subject></subj-group><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>The <styled-content style="fixed-case">AKT</styled-content>1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells</article-title><alt-title alt-title-type="left-running-head">Correspondence</alt-title></title-group><contrib-group><contrib id="bjh13542-cr-0001" contrib-type="author"><name><surname>Hofbauer</surname><given-names>Sebastian W.</given-names></name><xref ref-type="aff" rid="bjh13542-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13542-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-note" rid="bjh13542-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="bjh13542-cr-0002" contrib-type="author"><name><surname>Krenn</surname><given-names>Peter W.</given-names></name><xref ref-type="aff" rid="bjh13542-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13542-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-note" rid="bjh13542-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="bjh13542-cr-0003" contrib-type="author"><name><surname>Pi&#x000f1;&#x003cc;n Hofbauer</surname><given-names>Josefina</given-names></name><xref ref-type="aff" rid="bjh13542-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13542-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13542-cr-0004" contrib-type="author"><name><surname>Pucher</surname><given-names>Susanne</given-names></name><xref ref-type="aff" rid="bjh13542-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13542-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13542-cr-0005" contrib-type="author"><name><surname>Asslaber</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="bjh13542-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13542-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13542-cr-0006" contrib-type="author"><name><surname>Egle</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="bjh13542-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13542-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13542-cr-0007" contrib-type="author"><name><surname>Hartmann</surname><given-names>Tanja N.</given-names></name><address><email>t.hartmann@salk.at</email></address><xref ref-type="aff" rid="bjh13542-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13542-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13542-cr-0008" contrib-type="author"><name><surname>Greil</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="bjh13542-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13542-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="bjh13542-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Laboratory for Immunological and Molecular Cancer Research</named-content><named-content content-type="organisation-division">3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology</named-content><named-content content-type="organisation-division">Oncological Centre</named-content><institution>Paracelsus Medical University</institution><named-content content-type="city">Salzburg</named-content><named-content content-type="city">Austria</named-content></aff><aff id="bjh13542-aff-0002"><label><sup>2</sup></label><institution>Salzburg Cancer Research Institute</institution><named-content content-type="city">Salzburg</named-content><country country="AT">Austria</country></aff><author-notes><fn fn-type="equal" id="bjh13542-note-0001"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2016</year></pub-date><volume>172</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/bjh.2016.172.issue-5</issue-id><fpage>815</fpage><lpage>819</lpage><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. <italic>British Journal of Haematology</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:BJH-172-815.pdf"/><kwd-group kwd-group-type="author-generated"><kwd id="bjh13542-kwd-0001">chronic lymphocytic leukaemia</kwd><kwd id="bjh13542-kwd-0002"><styled-content style="fixed-case">AKT</styled-content></kwd><kwd id="bjh13542-kwd-0003">microenvironment</kwd><kwd id="bjh13542-kwd-0004">survival</kwd><kwd id="bjh13542-kwd-0005">chemoresistance</kwd></kwd-group><funding-group><award-group><funding-source>Austrian Science Fund FWF</funding-source><award-id>SFB&#x02010;P021</award-id><award-id>P26421&#x02010;B13</award-id></award-group></funding-group><funding-group><award-group><funding-source>Paracelsus Medical University Salzburg</funding-source><award-id>PMU&#x02010;FFF E&#x02010;10/11/058&#x02010;HAR</award-id><award-id>E&#x02010;12/15/074&#x02010;HAH</award-id></award-group></funding-group><funding-group><award-group><funding-source>SCRI&#x02010;LIMCR GmbH</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Province of Salzburg</funding-source></award-group></funding-group><counts><page-count count="5"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>bjh13542</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.6 mode:remove_FC converted:15.04.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The pathophysiology of chronic lymphocytic leukaemia (CLL) is characterised by a dynamic equilibrium of resting and proliferative tumour cells. While CLL cells in the peripheral blood are mostly G<sub>0</sub>&#x02010;arrested, those residing in lymphoid organs have an activated signature due to supportive signals from diverse immune and stromal cell types (Herishanu <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0003" ref-type="ref">2011</xref>). The clinical success of novel small molecule inhibitors targeting Bruton tyrosine kinase, such as Ibrutinib, and phosphatidylinositol&#x02010;3 kinase (PI3K), such as Idelalisib, strengthens the idea that signals downstream of the B cell receptor are critical for CLL development and progression. In this context, the protein kinase C (PKC) and PI3K pathways are indisputable chief players (for review see Woyach <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0008" ref-type="ref">2012</xref>). We and others have shown that downstream of PI3K and PKC&#x02010;beta, the serine/threonine kinase AKT, also known as protein kinase B (PKB), regulates various signalling cascades involved in survival (Hofbauer <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0004" ref-type="ref">2010</xref>; Zhuang <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0010" ref-type="ref">2010</xref>). AKT is encoded by three distinct genes, namely <italic>AKT1</italic>,<italic> AKT2</italic> and <italic>AKT3</italic> (also termed <italic>PKB&#x02010;alpha</italic>,<italic> PKB&#x02010;beta</italic>,<italic> PKB&#x02010;gamma</italic>, respectively). <italic>AKT1</italic> and <italic>AKT2</italic> are ubiquitously expressed whereas <italic>AKT3</italic> is mainly expressed in testes and brain (Yang <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0009" ref-type="ref">2003</xref>). In this study, we aimed to gain insight into isoform&#x02010;specific expression of AKT, and the contribution of AKT1 and AKT2 to stromal and activated T cell&#x02010;mediated survival and chemoresistance in CLL.</p><p>Peripheral blood samples from CLL patients were collected after informed consent was obtained in accordance with the Declaration of Helsinki and under the ethical approval of the Ethics Commission of the Province of Salzburg (415&#x02010;E/1287/4&#x02013;2011, 415&#x02010;E/1287/8&#x02013;2011).</p><p>First, analysing basal AKT isoform expression in unstimulated purified CLL cells, we observed increased <italic>AKT2</italic> mRNA and AKT2 protein expression as compared to AKT1 (Fig&#x000a0;<xref rid="bjh13542-fig-0001" ref-type="fig">1</xref>A and B). As we had previously noted increased AKT phosphorylation in CLL stromal cell co&#x02010;cultures (Hofbauer <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0004" ref-type="ref">2010</xref>), we evaluated AKT phosphorylation kinetics and isoform contribution to this phenomenon. AKT was rapidly phosphorylated at serine 473 (pS473), a phosphorylation site crucial for full AKT activation (Sarbassov <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0007" ref-type="ref">2005</xref>), and remained in the activated form for at least 24&#x000a0;h (Fig&#x000a0;<xref rid="bjh13542-fig-0001" ref-type="fig">1</xref>Ci). To assess the relative activation of AKT1 <italic>versus</italic> AKT2 in CLL cells co&#x02010;cultured with primary stromal cells, we analysed the phosphorylation at Ser473 (AKT1) and Ser474 (AKT2). We observed robust stromal cell&#x02010;induced AKT activation of both isoforms in CLL cells cultured in direct cell&#x02010;cell contact with stromal cells (Fig&#x000a0;<xref rid="bjh13542-fig-0001" ref-type="fig">1</xref>Cii), but not in CLL cells separated from the stromal layer by a transwell insert (Fig&#x000a0;<xref rid="bjh13542-fig-0001" ref-type="fig">1</xref>Di). AKT activation was associated with increased cell viability (Fig&#x000a0;<xref rid="bjh13542-fig-0001" ref-type="fig">1</xref>Dii).</p><fig fig-type="Figure" xml:lang="en" id="bjh13542-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>
<styled-content style="fixed-case">AKT</styled-content>1 is the dominant <styled-content style="fixed-case">AKT</styled-content> isoform in stromal cell mediated chronic lymphocytic leukaemia (<styled-content style="fixed-case">CLL</styled-content>) cell survival. (A) <italic><styled-content style="fixed-case">AKT</styled-content>1</italic> and <italic><styled-content style="fixed-case">AKT</styled-content>2 </italic>
<styled-content style="fixed-case">mRNA</styled-content> expression in <styled-content style="fixed-case">CD</styled-content>19&#x02010;positive selected <styled-content style="fixed-case">CLL</styled-content> cells (<italic>n</italic>&#x000a0;=&#x000a0;10) were measured by quantitative real&#x02010;time polymerase chain reaction (<styled-content style="fixed-case">RT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content>) using Taqman Gene Expression Assays relative to <italic><styled-content style="fixed-case">RPS</styled-content>18 </italic>
<styled-content style="fixed-case">rRNA</styled-content> expression. (B) <styled-content style="fixed-case">AKT</styled-content>1 and <styled-content style="fixed-case">AKT</styled-content>2 protein expression in purified <styled-content style="fixed-case">CLL</styled-content> cells was determined by Western blot, analysed densitometrically and compared to the housekeeping gene <italic><styled-content style="fixed-case">PPIA</styled-content></italic> (<italic>n</italic>&#x000a0;=&#x000a0;10). (C i) <styled-content style="fixed-case">CLL</styled-content> cells were cultured for the indicated time points or (C ii) for 24&#x000a0;h on stromal cells (<styled-content style="fixed-case">SC</styled-content>) and <styled-content style="fixed-case">AKT</styled-content> phosphorylation was determined by Western blot. (D i) <styled-content style="fixed-case">AKT</styled-content> phosphorylation and (D ii) <styled-content style="fixed-case">CLL</styled-content> cell survival was measured by fluorescence&#x02010;activated cell sorting (<styled-content style="fixed-case">FACS</styled-content>) analysis upon co&#x02010;culture of <styled-content style="fixed-case">CLL</styled-content> cells with primary <styled-content style="fixed-case">SC</styled-content>, either separated by membrane filter with 0&#x000b7;4&#x000a0;&#x003bc;m pore size (transwell), or in direct cell cell&#x02010;contact (<italic>n</italic>&#x000a0;=&#x000a0;6). Annexin&#x02010;V and 7&#x02010;aminoactinomycin D double negative cells were considered viable. (E) Upon an <styled-content style="fixed-case">AKT</styled-content> isoform&#x02010;specific protein G&#x02010;coupled bead&#x02010;based pull&#x02010;down assay, <styled-content style="fixed-case">AKT</styled-content> isoform expression and <styled-content style="fixed-case">GSK</styled-content>3A/B phosphorylation in <styled-content style="fixed-case">MEC</styled-content>1 cells was analysed by Western blot. (F) Flow cytometric determination of cell viability of <styled-content style="fixed-case">SC</styled-content> co&#x02010;cultured <styled-content style="fixed-case">CLL</styled-content> cells after 48&#x000a0;h of pan&#x02010;<styled-content style="fixed-case">AKT</styled-content> (5&#x000a0;&#x003bc;mol/l of <styled-content style="fixed-case">MK</styled-content>2206 or AiX) or <styled-content style="fixed-case">AKT</styled-content>2 isoform specific (Akti&#x02010;2, 5&#x000a0;&#x003bc;mol/l) inhibition (<italic>n</italic>&#x000a0;=&#x000a0;5). (G) si<styled-content style="fixed-case">RNA</styled-content>&#x02010;mediated <styled-content style="fixed-case">AKT</styled-content> isoform&#x02010;specific knockdown in <styled-content style="fixed-case">MEC</styled-content>1 cells was achieved using the Nucleofector<sup>&#x02122;</sup> Technology (Lonza, Basel, Switzerland), and knockdown efficiency was determined by <styled-content style="fixed-case">RT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content>. (H) Following knockdown, <styled-content style="fixed-case">MEC</styled-content>1 cell viability was assessed after 48&#x000a0;h of culture by <styled-content style="fixed-case">FACS</styled-content> analysis and compared to the non&#x02010;targeting control (<italic>n</italic>&#x000a0;=&#x000a0;4). All panels: dark horizontal lines represent the median, with the box representing the 25th and 75th percentiles, the whiskers the smallest and largest value. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, <styled-content style="fixed-case">CA</styled-content>,<styled-content style="fixed-case"> USA</styled-content>). All data were tested for normal distribution. Analysis of variance (<sc>anova</sc>) and Tukey post tests were performed for normally distributed data. For non&#x02010;normally distributed data, the Friedman and Dunns test was used. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;05; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;01; ***<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;001; n.s., non significant.</p></caption><graphic id="nlm-graphic-1" xlink:href="BJH-172-815-g001"/></fig><p>Next, we treated co&#x02010;cultured CLL cells with several AKT inhibitors. As there is no AKT1&#x02010;specific inhibitor available, we used the pan&#x02010;AKT inhibitors MK2206 and AiX, and the AKT2&#x02010;selective inhibitor, Akti&#x02010;2. The specificities of these inhibitors were confirmed by an AKT isoform&#x02010;specific pull&#x02010;down and subsequent <italic>in&#x000a0;vitro</italic> kinase assay to detect phosphorylation of the AKT substrate GSK3A/B after MK2206 or Akti&#x02010;2 treatment of the Epstein&#x02010;Barr virus&#x02010;positive CLL patient&#x02010;derived MEC1 cells (Fig&#x000a0;<xref rid="bjh13542-fig-0001" ref-type="fig">1</xref>E). Applying the inhibitors to primary CLL cells co&#x02010;cultured with stromal cells indicated that the selective inhibition of AKT2 did not decrease cell viability, whereas pan&#x02010;AKT inhibition resulted in significantly decreased survival (Fig&#x000a0;<xref rid="bjh13542-fig-0001" ref-type="fig">1</xref>F), suggesting a dominance of AKT1 or a cooperation of both isoforms in maintaining cell vitality. Genetic manipulations in primary CLL cells are hard to achieve, therefore, to address these alternatives, we used a siRNA approach to target <italic>AKT1</italic> or <italic>AKT2</italic> in MEC1 cells. Successful and similar knockdown efficiencies were achieved in both experimental settings (Fig&#x000a0;<xref rid="bjh13542-fig-0001" ref-type="fig">1</xref>G). However, the transient knockdown of <italic>AKT1</italic>, but not <italic>AKT2</italic>, resulted in loss of cell viability, establishing AKT1 as the dominant AKT isoform (Fig&#x000a0;<xref rid="bjh13542-fig-0001" ref-type="fig">1</xref>H). Consistently, simultaneous knockdown of both isoforms did not further reduce viability compared to the single <italic>AKT1</italic> knockdown (Fig&#x000a0;<xref rid="bjh13542-fig-0001" ref-type="fig">1</xref>H).</p><p>Chronic lymphocytic leukaemia cells co&#x02010;cultured with activated T cells are rapidly activated, allowing us to mimic <italic>in&#x000a0;vitro</italic> at least part of the proliferative processes that take place in lymph nodes (Asslaber <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0001" ref-type="ref">2013</xref>). Under these co&#x02010;culture conditions, we observed significant transcriptional upregulation of both <italic>AKT1</italic> and <italic>AKT2</italic> within 24&#x000a0;h (Fig&#x000a0;<xref rid="bjh13542-fig-0002" ref-type="fig">2</xref>A), which was accompanied by phosphorylation of both isoforms on the protein level (Fig&#x000a0;<xref rid="bjh13542-fig-0002" ref-type="fig">2</xref>B).</p><fig fig-type="Figure" xml:lang="en" id="bjh13542-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>
<styled-content style="fixed-case">AKT</styled-content>1 phosphorylation and regulation by <styled-content style="fixed-case">STAT</styled-content>3 upon T cell&#x02010;mediated activation results in fludarabine resistance. Peripheral blood mononuclear cells from chronic lymphocytic leukaemia (<styled-content style="fixed-case">CLL</styled-content>) patients containing &#x0003e;5% T cells were activated by addition of anti&#x02010;<styled-content style="fixed-case">CD</styled-content>3/<styled-content style="fixed-case">CD</styled-content>28 beads (<styled-content style="fixed-case">CD</styled-content>3/<styled-content style="fixed-case">CD</styled-content>28), harvested, and purified at the indicated time points. (A) <italic><styled-content style="fixed-case">AKT</styled-content>1</italic> (left panel) and <italic><styled-content style="fixed-case">AKT</styled-content>2</italic> (right panel) <styled-content style="fixed-case">mRNA</styled-content> levels were determined by real&#x02010;time polymerase chain reaction (<styled-content style="fixed-case">RT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content>) as described before and compared to the untreated control (<italic>n</italic>&#x000a0;=&#x000a0;10). (B) The activation state of <styled-content style="fixed-case">AKT</styled-content> isoforms was analysed by Western blot. (C) The activation state of <styled-content style="fixed-case">STAT</styled-content>3 (<styled-content style="fixed-case">pY</styled-content>(705)) in resting or activated <styled-content style="fixed-case">CLL</styled-content> cells in the absence or presence of the <styled-content style="fixed-case">STAT</styled-content>3 inhibitor S3I&#x02010;201 (50&#x000a0;&#x003bc;mol/l) was determined by Western blot. (D) <italic><styled-content style="fixed-case">AKT</styled-content>1 </italic>
<styled-content style="fixed-case">mRNA</styled-content> expression in activated <styled-content style="fixed-case">CLL</styled-content> cells upon <styled-content style="fixed-case">STAT</styled-content>3 inhibition was determined by <styled-content style="fixed-case">RT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content> (<italic>n</italic>&#x000a0;=&#x000a0;4) (results presented as bars depict the mean&#x000a0;+&#x000a0;standard deviation values, data normalised to resting, untreated control). (E) The viability of activated, fludarabine&#x02010;resistant <styled-content style="fixed-case">CLL</styled-content> cells was measured after 48&#x000a0;h and compared to the treatment with the single agents fludarabine (10&#x000a0;&#x003bc;mol/l), the pan&#x02010;<styled-content style="fixed-case">AKT</styled-content> inhibitor <styled-content style="fixed-case">MK</styled-content>2206 (5&#x000a0;&#x003bc;mol/l), the <styled-content style="fixed-case">AKT</styled-content>2 specific inhibitor Akti&#x02010;2 (5&#x000a0;&#x003bc;mol/l), the <styled-content style="fixed-case">STAT</styled-content>3 inhibitor S3I&#x02010;201 (50&#x000a0;&#x003bc;mol/l) or the indicated combinations (<italic>n</italic>&#x000a0;=&#x000a0;6; dark horizontal lines represent the median, with the box representing the 25th and 75th percentiles, and the whiskers the smallest and largest value). Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, <styled-content style="fixed-case">CA</styled-content>,<styled-content style="fixed-case"> USA</styled-content>). All data were tested for normal distribution, and <italic>t</italic>&#x02010;test or analysis of variance (<sc>anova</sc>) and Tukey post test were performed for normally distributed data. For non&#x02010;normally distributed data, the Wilcoxon signed ranked test or the Friedman and Dunns test were used. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;05; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;01; ***<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;001.</p></caption><graphic id="nlm-graphic-3" xlink:href="BJH-172-815-g002"/></fig><p>We next studied AKT isoform activation in the context of the oncogene <italic>STAT3</italic>, a factor of clinical significance to CLL, which has been described to directly interact with the <italic>AKT1</italic> promoter (Park <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0006" ref-type="ref">2005</xref>; Hazan&#x02010;Halevy <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0002" ref-type="ref">2010</xref>). Activation of CLL cells by T cells resulted in pronounced STAT3 signalling (pY(705)&#x02010;STAT3), which could be antagonised by treatment with the STAT3 inhibitor S3I&#x02010;201 (Fig&#x000a0;<xref rid="bjh13542-fig-0002" ref-type="fig">2</xref>C). STAT3 inhibition significantly decreased <italic>AKT1</italic> mRNA expression (Fig&#x000a0;<xref rid="bjh13542-fig-0002" ref-type="fig">2</xref>D), indicating an interaction of these pathways upon CLL cell activation. Notably, relative AKT isoform transcription and protein expression in activated CLL cells was not altered upon treatment with the novel small molecule inhibitors Ibrutinib or Idelalisib (data not shown).</p><p>These observations prompted us to investigate potential synergistic effects of AKT&#x02010; or STAT3&#x02010;inhibition with conventional drugs used in the treatment of CLL. We recently observed that T cell activated&#x02010;CLL cells gain resistance towards fludarabine (Hofbauer <italic>et&#x000a0;al</italic>, <xref rid="bjh13542-bib-0005" ref-type="ref">2014</xref>). Consistently, CLL cells co&#x02010;cultured with activated T cells remained viable for up to 48&#x000a0;h even in the presence of fludarabine. However, exposure to the pan&#x02010;AKT or STAT3 inhibitor induced CLL cell apoptosis within 24&#x000a0;h (data not shown), indicating that inhibition of AKT or STAT3 is able to overcome CLL activation&#x02010;induced protection. Notably, after 48&#x000a0;h of culture, CLL cells exposed to the STAT3 inhibitor underwent strong apoptosis irrespective of the presence of fludarabine. Pan&#x02010;AKT inhibition, but importantly not AKT2 inhibition, resulted in decreased cell viability levels, which were significantly pronounced when combined with fludarabine (Fig&#x000a0;<xref rid="bjh13542-fig-0002" ref-type="fig">2</xref>E).</p><p>Taken together, our results indicate a dominant role of AKT1 in microenvironment&#x02010;mediated CLL survival and chemoresistance. CLL patients could particularly benefit from targeting the predominant AKT1 isoform, which may also increase the response rate towards classical chemotherapeutics.</p><sec id="bjh13542-sec-0003"><title>Author contributions</title><p>SWH, PWK, JHP, SP, DA performed research; SWH, PWK, TNH designed research and interpreted data; SWH, PWK, SP, JFP, DA analysed data; RG contributed reagents and analytical tools and interpreted data; SWH, PWK and TNH wrote the manuscript. All authors were involved in critical discussion.</p></sec><sec id="bjh13542-sec-0004"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec></body><back><ack id="bjh13542-sec-0002"><title>Acknowledgements</title><p>We would like to thank all patients and their clinicians for their participation in this study. This work has been supported by the Austrian Science Fund FWF (SFB&#x02010;P021 to R. Greil, P26421&#x02010;B13 to T.N. Hartmann), the Paracelsus Medical University Salzburg (PMU&#x02010;FFF E&#x02010;10/11/058&#x02010;HAR and E&#x02010;12/15/074&#x02010;HAH to T.N. Hartmann), the SCRI&#x02010;LIMCR GmbH, and the Province of Salzburg.</p></ack><ref-list content-type="cited-references" id="bjh13542-bibl-0001"><title>References</title><ref id="bjh13542-bib-0001"><mixed-citation publication-type="journal" id="bjh13542-cit-0001">
<string-name>
<surname>Asslaber</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Grossinger</surname>, <given-names>E.M.</given-names>
</string-name>, <string-name>
<surname>Girbl</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Hofbauer</surname>, <given-names>S.W.</given-names>
</string-name>, <string-name>
<surname>Egle</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Greil</surname>, <given-names>R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Hartmann</surname>, <given-names>T.N.</given-names>
</string-name> (<year>2013</year>) <article-title>Mimicking the microenvironment in chronic lymphocytic leukaemia &#x02013; where does the journey go?</article-title>
<source>British Journal of Haematology</source>, <volume>160</volume>, <fpage>711</fpage>&#x02013;<lpage>714</lpage>.<pub-id pub-id-type="pmid">23205585</pub-id></mixed-citation></ref><ref id="bjh13542-bib-0002"><mixed-citation publication-type="journal" id="bjh13542-cit-0002">
<string-name>
<surname>Hazan&#x02010;Halevy</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Harris</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Shanker</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ferrajoli</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Keating</surname>, <given-names>M.J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Estrov</surname>, <given-names>Z.</given-names>
</string-name> (<year>2010</year>) <article-title>STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells</article-title>. <source>Blood</source>, <volume>115</volume>, <fpage>2852</fpage>&#x02013;<lpage>2863</lpage>.<pub-id pub-id-type="pmid">20154216</pub-id></mixed-citation></ref><ref id="bjh13542-bib-0003"><mixed-citation publication-type="journal" id="bjh13542-cit-0003">
<string-name>
<surname>Herishanu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Perez&#x02010;Galan</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Biancotto</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Pittaluga</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Vire</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Gibellini</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Njuguna</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Stennett</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Raghavachari</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>McCoy</surname>, <given-names>J.P.</given-names>
</string-name>, <string-name>
<surname>Raffeld</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Stetler&#x02010;Stevenson</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Sherry</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Arthur</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Maric</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>White</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Marti</surname>, <given-names>G.E.</given-names>
</string-name>, <string-name>
<surname>Munson</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>, <given-names>W.H.</given-names>
</string-name> &#x00026; <string-name>
<surname>Wiestner</surname>, <given-names>A.</given-names>
</string-name> (<year>2011</year>) <article-title>The lymph node microenvironment promotes B&#x02010;cell receptor signaling, NF&#x02010;kappaB activation, and tumor proliferation in chronic lymphocytic leukemia</article-title>. <source>Blood</source>, <volume>117</volume>, <fpage>563</fpage>&#x02013;<lpage>574</lpage>.<pub-id pub-id-type="pmid">20940416</pub-id></mixed-citation></ref><ref id="bjh13542-bib-0004"><mixed-citation publication-type="journal" id="bjh13542-cit-0004">
<string-name>
<surname>Hofbauer</surname>, <given-names>S.W.</given-names>
</string-name>, <string-name>
<surname>Pinon</surname>, <given-names>J.D.</given-names>
</string-name>, <string-name>
<surname>Brachtl</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Haginger</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Johrer</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Tinhofer</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Hartmann</surname>, <given-names>T.N.</given-names>
</string-name> &#x00026; <string-name>
<surname>Greil</surname>, <given-names>R.</given-names>
</string-name> (<year>2010</year>) <article-title>Modifying akt signaling in B&#x02010;cell chronic lymphocytic leukemia cells</article-title>. <source>Cancer Research</source>, <volume>70</volume>, <fpage>7336</fpage>&#x02013;<lpage>7344</lpage>.<pub-id pub-id-type="pmid">20823161</pub-id></mixed-citation></ref><ref id="bjh13542-bib-0005"><mixed-citation publication-type="journal" id="bjh13542-cit-0005">
<string-name>
<surname>Hofbauer</surname>, <given-names>S.W.</given-names>
</string-name>, <string-name>
<surname>Krenn</surname>, <given-names>P.W.</given-names>
</string-name>, <string-name>
<surname>Ganghammer</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Asslaber</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Pichler</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Oberascher</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Henschler</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Wallner</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kerschbaum</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Greil</surname>, <given-names>R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Hartmann</surname>, <given-names>T.N.</given-names>
</string-name> (<year>2014</year>) <article-title>Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells</article-title>. <source>Blood</source>, <volume>123</volume>, <fpage>2181</fpage>&#x02013;<lpage>2188</lpage>.<pub-id pub-id-type="pmid">24501217</pub-id></mixed-citation></ref><ref id="bjh13542-bib-0006"><mixed-citation publication-type="journal" id="bjh13542-cit-0006">
<string-name>
<surname>Park</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Kaneko</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Szewczyk</surname>, <given-names>K.M.</given-names>
</string-name>, <string-name>
<surname>Nicosia</surname>, <given-names>S.V.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Jove</surname>, <given-names>R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Cheng</surname>, <given-names>J.Q.</given-names>
</string-name> (<year>2005</year>) <article-title>Molecular cloning and characterization of the human AKT1 promoter uncovers its up&#x02010;regulation by the Src/Stat3 pathway</article-title>. <source>Journal of Biological Chemistry</source>, <volume>280</volume>, <fpage>38932</fpage>&#x02013;<lpage>38941</lpage>.<pub-id pub-id-type="pmid">16174774</pub-id></mixed-citation></ref><ref id="bjh13542-bib-0007"><mixed-citation publication-type="journal" id="bjh13542-cit-0007">
<string-name>
<surname>Sarbassov</surname>, <given-names>D.D.</given-names>
</string-name>, <string-name>
<surname>Guertin</surname>, <given-names>D.A.</given-names>
</string-name>, <string-name>
<surname>Ali</surname>, <given-names>S.M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Sabatini</surname>, <given-names>D.M.</given-names>
</string-name> (<year>2005</year>) <article-title>Phosphorylation and regulation of Akt/PKB by the rictor&#x02010;mTOR complex</article-title>. <source>Science</source>, <volume>307</volume>, <fpage>1098</fpage>&#x02013;<lpage>1101</lpage>.<pub-id pub-id-type="pmid">15718470</pub-id></mixed-citation></ref><ref id="bjh13542-bib-0008"><mixed-citation publication-type="journal" id="bjh13542-cit-0008">
<string-name>
<surname>Woyach</surname>, <given-names>J.A.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>, <given-names>A.J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Byrd</surname>, <given-names>J.C.</given-names>
</string-name> (<year>2012</year>) <article-title>The B&#x02010;cell receptor signaling pathway as a therapeutic target in CLL</article-title>. <source>Blood</source>, <volume>120</volume>, <fpage>1175</fpage>&#x02013;<lpage>1184</lpage>.<pub-id pub-id-type="pmid">22715122</pub-id></mixed-citation></ref><ref id="bjh13542-bib-0009"><mixed-citation publication-type="journal" id="bjh13542-cit-0009">
<string-name>
<surname>Yang</surname>, <given-names>Z.Z.</given-names>
</string-name>, <string-name>
<surname>Tschopp</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Hemmings&#x02010;Mieszczak</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Feng</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Brodbeck</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Perentes</surname>, <given-names>E.</given-names>
</string-name> &#x00026; <string-name>
<surname>Hemmings</surname>, <given-names>B.A.</given-names>
</string-name> (<year>2003</year>) <article-title>Protein kinase B alpha/Akt1 regulates placental development and fetal growth</article-title>. <source>The Journal of Biological Chemistry</source>, <volume>278</volume>, <fpage>32124</fpage>&#x02013;<lpage>32131</lpage>.<pub-id pub-id-type="pmid">12783884</pub-id></mixed-citation></ref><ref id="bjh13542-bib-0010"><mixed-citation publication-type="journal" id="bjh13542-cit-0010">
<string-name>
<surname>Zhuang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hawkins</surname>, <given-names>S.F.</given-names>
</string-name>, <string-name>
<surname>Glenn</surname>, <given-names>M.A.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>, <given-names>G.G.</given-names>
</string-name>, <string-name>
<surname>Carter</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Cawley</surname>, <given-names>J.C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Pettitt</surname>, <given-names>A.R.</given-names>
</string-name> (<year>2010</year>) <article-title>Akt is activated in chronic lymphocytic leukemia cells and delivers a pro&#x02010;survival signal: the therapeutic potential of Akt inhibition</article-title>. <source>Haematologica</source>, <volume>95</volume>, <fpage>110</fpage>&#x02013;<lpage>118</lpage>.<pub-id pub-id-type="pmid">19713228</pub-id></mixed-citation></ref></ref-list></back></article>